Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Talpaz

Showing results (231-240 of 350) with videos related to

Pageof 35
Sort By:
Blood|April 21, 2001
Autocrine cell suicide in a Burkitt lymphoma cell line (Daudi) induced by interferon alpha: involvement of tumor necrosis factor as ligand for the CD95 receptorH Gisslinger, R Kurzrock, B Gisslinger, et al.
JAMA|January 13, 1984
Chronic immune stimulation by sperm alloantigens. Support for the hypothesis that spermatozoa induce immune dysregulation in homosexual malesG M Mavligit, M Talpaz, F T Hsia, et al.
Blood|February 15, 1992
Polyclonal hematopoiesis in interferon-induced cytogenetic remissions of chronic myelogenous leukemiaD Claxton, A Deisseroth, M Talpaz, et al.
Cancer Research|June 1, 1985
Pharmacokinetics, single-dose tolerance, and biological activity of recombinant gamma-interferon in cancer patientsR Kurzrock, M G Rosenblum, S A Sherwin, et al.
Blood|December 15, 1995
Effect of interleukin-1 beta converting enzyme inhibitor on acute myelogenous leukemia progenitor proliferationZ Estrov, R A Black, P R Sleath, et al.
Blood|April 15, 1992
Inhibition of acute myelogenous leukemia blast proliferation by interleukin-1 (IL-1) receptor antagonist and soluble IL-1 receptorsZ Estrov, R Kurzrock, E Estey, et al.
Blood|June 1, 1989
Detection of two alternative bcr/abl mRNA junctions and minimal residual disease in Philadelphia chromosome positive chronic myelogenous leukemia by polymerase chain reactionM S Lee, A LeMaistre, H M Kantarjian, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 1986
Phase I study of multiple dose intramuscularly administered recombinant gamma interferonR Kurzrock, J R Quesada, M Talpaz, et al.
Leukemia|September 10, 2005
Imatinib mesylate suppresses cytokine synthesis by activated CD4 T cells of patients with chronic myelogenous leukemiaH Gao, B-N Lee, M Talpaz, et al.
Leukemia|August 2, 2016
A phase I, open-label, dose-escalation, multicenter study of the JAK2 inhibitor NS-018 in patients with myelofibrosisS Verstovsek, M Talpaz, E Ritchie, et al.
Pageof 35

Showing results (231-240 of 350) with videos related to

Sort By:
Pageof 35
Blood|April 21, 2001
Autocrine cell suicide in a Burkitt lymphoma cell line (Daudi) induced by interferon alpha: involvement of tumor necrosis factor as ligand for the CD95 receptorH Gisslinger, R Kurzrock, B Gisslinger, et al.
JAMA|January 13, 1984
Chronic immune stimulation by sperm alloantigens. Support for the hypothesis that spermatozoa induce immune dysregulation in homosexual malesG M Mavligit, M Talpaz, F T Hsia, et al.
Blood|February 15, 1992
Polyclonal hematopoiesis in interferon-induced cytogenetic remissions of chronic myelogenous leukemiaD Claxton, A Deisseroth, M Talpaz, et al.
Cancer Research|June 1, 1985
Pharmacokinetics, single-dose tolerance, and biological activity of recombinant gamma-interferon in cancer patientsR Kurzrock, M G Rosenblum, S A Sherwin, et al.
Blood|December 15, 1995
Effect of interleukin-1 beta converting enzyme inhibitor on acute myelogenous leukemia progenitor proliferationZ Estrov, R A Black, P R Sleath, et al.
Blood|April 15, 1992
Inhibition of acute myelogenous leukemia blast proliferation by interleukin-1 (IL-1) receptor antagonist and soluble IL-1 receptorsZ Estrov, R Kurzrock, E Estey, et al.
Blood|June 1, 1989
Detection of two alternative bcr/abl mRNA junctions and minimal residual disease in Philadelphia chromosome positive chronic myelogenous leukemia by polymerase chain reactionM S Lee, A LeMaistre, H M Kantarjian, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 1986
Phase I study of multiple dose intramuscularly administered recombinant gamma interferonR Kurzrock, J R Quesada, M Talpaz, et al.
Leukemia|September 10, 2005
Imatinib mesylate suppresses cytokine synthesis by activated CD4 T cells of patients with chronic myelogenous leukemiaH Gao, B-N Lee, M Talpaz, et al.
Leukemia|August 2, 2016
A phase I, open-label, dose-escalation, multicenter study of the JAK2 inhibitor NS-018 in patients with myelofibrosisS Verstovsek, M Talpaz, E Ritchie, et al.
Pageof 35